Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Classical hematology 2Plasma cell 1Other neoplasm 1

Conditions

Myelodysplastic Syndromes 52Leukemia, Myeloid, Acute 51Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myeloproliferative Disorders 24Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 15Primary Myelofibrosis 12Leukemia 11Hodgkin Disease 11Polycythemia Vera 9Neuroblastoma 9Histiocytosis, Langerhans-Cell 9Glioma 9Wilms Tumor 8Sarcoma 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Hepatoblastoma 8Ependymoma 8Anemia, Refractory, with Excess of Blasts 8Rhabdomyosarcoma 7Osteosarcoma 7Myelodysplastic-Myeloproliferative Diseases 7Leukemia, Biphenotypic, Acute 7Blast Crisis 7Thrombocythemia, Essential 6Multiple Myeloma 6Blastic Plasmacytoid Dendritic Cell Neoplasm 6

Interventions

ruxolitinib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hematologic Diseases × Myeloid × 30 days × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT07379125 2026-05-22

Therapeutic RSK1 Targeting in Myelofibrosis

Washington University School of Medicine

Phase 1 Recruiting
18 enrolled
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Splenomegaly, Bone Marrow Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡